Globus Medical, Inc. revised earnings guidance for the year 2023. The company increased its full-year fiscal 2023 revenue guidance to $1.55 billion, up from $1.125 billion, and reaffirmed non-GAAP fully diluted earnings per share guidance of $2.30.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.61 USD | -0.46% |
|
+0.75% | +23.12% |
29/05 | BTIG Adjusts Globus Medical's Price Target to $72 From $63, Keeps Buy Rating | MT |
20/05 | Piper Sandler Upgrades Globus Medical to Overweight From Neutral, Adjusts Price Target to $80 From $60 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.12% | 8.86B | |
-5.81% | 180B | |
-1.63% | 106B | |
-4.14% | 67.55B | |
-6.56% | 46.11B | |
+13.22% | 45.79B | |
+2.58% | 41.61B | |
+19.93% | 31.07B | |
+11.40% | 24.77B | |
-5.36% | 24.27B |
- Stock Market
- Equities
- GMED Stock
- News Globus Medical, Inc.
- Globus Medical, Inc. Revises Earnings Guidance for the Year 2023